ArticleScientific reports2025
Remnant cholesterol and body mass index jointly associate with cardiometabolic Multimorbidity with mediation analysis in CHARLS a prospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The association between triglyceride glucose-frailty index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study.Cardiovascular diabetology · 2026Article
- Development and validation of a cardiometabolic multimorbidity prediction model in middle-aged and older adults.Scientific reports · 2026Article
- The Diagnostic Value of sdLDL-C for Acute Coronary Syndrome with Coexisting Hypertension and Carotid Atherosclerosis in Northeast China.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Remnant cholesterol (RC) has emerged as a novel lipid parameter reflecting the residual risk of atherogenic dyslipidemia beyond low-density lipoprotein cholesterol (LDL-C). Previous studies have demonstrated that elevated RC and increased body mass index (BMI) are each independently associated with cardiometabolic diseases such as diabetes and cardiovascular disorders. However, whether RC interacts with BMI and how their combined influence contributes to the development of cardiometabolic multimorbidity (CMM)-the coexistence of multiple cardiometabolic conditions-remain unclear. Clarifying these relationships may provide new insights into the metabolic mechanisms underlying multimorbidity and improve early risk stratification. This longitudinal cohort study used data from 6,646 adults aged ≥ 45 years in the China Health and Retirement Longitudinal Study (CHARLS). Cardiometabolic multimorbidity (CMM) was defined as having two or more physician-diagnosed conditions among heart disease, stroke, and diabetes. Associations of remnant cholesterol (RC) and body mass index (BMI) with CMM were examined using restricted cubic spline, multivariable regression, interaction, and bidirectional mediation analyses, adjusting for demographic, lifestyle, and metabolic factors. A total of 6,646 participants (mean age 58.52 years) were included. Both RC and BMI were significant independent risk factors for CMM with combined, with a joint association. Elevated RC (≥ median) significantly increased the risk of CMM (adjusted OR = 1.35, p = 0.003), whereas BMI showed a dose-dependent risk pattern, with adjusted ORs (95% CIs) of 1.32 (1.10-1.58) for overweight and 1.78 (1.42-2.22) for obesity compared with normal weight (p < 0.01). The combined effect of high RC and high BMI significantly increased CMM risk (adjusted OR = 2.23, p < 0.0001). In adjusted mediation models, BMI accounted for 32.6% of the total association of RC on CMM (β = 0.00021, P < 0.001), whereas RC accounted for 6.9% of the total effect of BMI on CMM (β = 0.00005, P = 0.016). This study suggests that elevated remnant cholesterol and higher BMI are jointly associated with increased cardiometabolic multimorbidity risk, underscoring the importance of considering lipid-related and metabolic factors together in risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.